October, 2007 - Results of phase III randomized trials show safety and efficacy is significantly improved when using Taxotere® based regimen.  Details here.

Taxotere^® Approved for Treatment of Oral and Head and Neck Cancer

October, 2006 - “This study has shown that induction therapy with a Taxotere®, cisplatin, fluorouracil (TPF) regimen increases survival. With this approval, I hope to see TPF become the standard of care for induction therapy for patients with this type of cancer.” - Marshall Poser, MD, Medical Director

• Details from FDA announcement

• Word document with announcement (346K)

A New Option for Oral and Head and Neck Cancer Treatment!

March, 2006 - Imclone and Bristol-Myer Squibb announce FDA approval of Erbitux as a new treatment option targeting squamous cell carcinoma of the head and neck.  This is good news for patients... new and recurrent.  Please explore the following links to read more about it!

• FDA News Release

• Survival Data (April, 2007)

• FDA Approves Erbitux - First Monoclonal Antibody Treatment for Head and Neck Cancer (March, 2006)

• Abstract: Radiotherapy Plus Erbitux for Treatment of Sqauamous Cell Carcinoma of the Head and Neck   

Home | About SPOHNC | Membership | Newsletters | Resources | Supportive Care | Email | Privacy | Chapters | Order | Clinical | Archives

 

---

Copyright © SPOHNC.org
1999-2009
All Rights Reserved